Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Luis Miguel Juárez-Salcedo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain.
- College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64804, USA.
- Primary Care Medicine, Adelfas Primary Care Center, 28007 Madrid, Spain.
- Hematology/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA.
ORCID-Profile: Luis Miguel Juárez-Salcedo, Santosh Nimkar
Zitieren
APA
Juárez-Salcedo, L. M., Nimkar, S., Corazón, A. M., & Dalia, S. (2024). Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147580
Vancouver
Juárez-Salcedo LM, Nimkar S, Corazón AM, Dalia S. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147580
BibTeX
@article{JurezSalcedo2024,
author = {Juárez-Salcedo, Luis Miguel and Nimkar, Santosh and Corazón, Ana María and Dalia, Samir},
title = {Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147580}
}
EUVIMED